Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.

Cancer Cell Biology Complement Oncology Radiation therapy

Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 11 01 2023
accepted: 05 10 2023
medline: 4 12 2023
pubmed: 12 10 2023
entrez: 12 10 2023
Statut: epublish

Résumé

An immunosuppressive microenvironment causes poor tumor T cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses in these tumors is still a challenge. Using an integrated screening approach to identify cancer-specific vulnerabilities, we identified complement receptor C5aR1 as a druggable target, which when inhibited improved radiotherapy, even in tumors displaying immunosuppressive features and poor CD8+ T cell infiltration. While C5aR1 is well-known for its role in the immune compartment, we found that C5aR1 is also robustly expressed on malignant epithelial cells, highlighting potential tumor cell-specific functions. C5aR1 targeting resulted in increased NF-κB-dependent apoptosis specifically in tumors and not normal tissues, indicating that, in malignant cells, C5aR1 primarily regulated cell fate. Collectively, these data revealed that increased complement gene expression is part of the stress response mounted by irradiated tumors and that targeting C5aR1 could improve radiotherapy, even in tumors displaying immunosuppressive features.

Identifiants

pubmed: 37824211
pii: 168277
doi: 10.1172/JCI168277
pmc: PMC10688992
doi:
pii:

Substances chimiques

Complement C5a 80295-54-1
Receptors, Complement 0
C5AR1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P01 CA067166
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE029672
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197713
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA257907
Pays : United States

Références

Cell Rep. 2014 Aug 7;8(3):818-30
pubmed: 25066124
Trends Biochem Sci. 2011 Mar;36(3):133-40
pubmed: 20947357
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Semin Immunol. 2013 Feb;25(1):54-64
pubmed: 23706991
ACS Omega. 2020 Jan 30;5(5):2345-2354
pubmed: 32064396
J Mol Biol. 2013 Apr 26;425(8):1302-17
pubmed: 23274142
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Technol Cancer Res Treat. 2007 Apr;6(2):111-21
pubmed: 17375973
Cell Stem Cell. 2022 Aug 4;29(8):1213-1228.e8
pubmed: 35931031
Nat Rev Immunol. 2008 Jan;8(1):48-58
pubmed: 18064050
Oncogene. 2016 Feb 11;35(6):793-9
pubmed: 25961932
Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
pubmed: 18594563
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
JAMA Oncol. 2018 Jun 14;4(6):e180071
pubmed: 29566109
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Nucleic Acids Res. 2021 Jan 8;49(D1):D1074-D1082
pubmed: 33219674
Sci Rep. 2017 Nov 30;7(1):16618
pubmed: 29192179
Genome Biol. 2014;15(12):550
pubmed: 25516281
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):793-9
pubmed: 17499451
Mol Cell. 2013 Dec 12;52(5):758-66
pubmed: 24268576
Sci Immunol. 2021 Dec 24;6(66):eabf2489
pubmed: 34932384
Mol Cell. 2019 Sep 19;75(6):1299-1314.e6
pubmed: 31353207
iScience. 2020 Sep 21;23(10):101594
pubmed: 33205012
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
Cancer Cell. 2022 Feb 14;40(2):168-184.e13
pubmed: 35120600
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cell Rep. 2022 May 31;39(9):110851
pubmed: 35649359
Sci Transl Med. 2014 May 14;6(236):236ra64
pubmed: 24828078
Immunity. 2015 Apr 21;42(4):767-77
pubmed: 25888260
Cancer Immunol Res. 2021 Aug;9(8):891-908
pubmed: 34039653
Curr Protoc Immunol. 2020 Sep;130(1):e106
pubmed: 32940424
J Immunother Cancer. 2022 Sep;10(9):
pubmed: 36137652
Semin Immunol. 2016 Jun;28(3):208-22
pubmed: 27321574
J Clin Oncol. 2006 Oct 1;24(28):4620-5
pubmed: 17008704
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Ther Adv Med Oncol. 2022 Feb 21;14:17588359221077972
pubmed: 35222695
Cancer Immunol Res. 2021 Aug;9(8):909-925
pubmed: 34039652
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Br J Surg. 2020 Jan;107(1):131-139
pubmed: 31625143

Auteurs

Callum Beach (C)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

David MacLean (D)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Dominika Majorova (D)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Stavros Melemenidis (S)

Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Dhanya K Nambiar (DK)

Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Ryan K Kim (RK)

Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Gabriel N Valbuena (GN)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Silvia Guglietta (S)

Department of Regenerative Medicine and Cell Biology.
Hollings Cancer Center, and.

Carsten Krieg (C)

Hollings Cancer Center, and.
Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

Mahnaz Darvish-Damavandi (M)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.

Tatsuya Suwa (T)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Alistair Easton (A)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Lily Vs Hillson (LV)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Ashley K McCulloch (AK)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Ross K McMahon (RK)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Kathryn Pennel (K)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Joanne Edwards (J)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Sean M O'Cathail (SM)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Campbell S Roxburgh (CS)

School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Enric Domingo (E)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Eui Jung Moon (EJ)

Department of Oncology, University of Oxford, Oxford, United Kingdom.
Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Dadi Jiang (D)

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Yanyan Jiang (Y)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Qingyang Zhang (Q)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Albert C Koong (AC)

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Trent M Woodruff (TM)

School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Edward E Graves (EE)

Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Tim Maughan (T)

Department of Oncology, University of Oxford, Oxford, United Kingdom.

Simon Ja Buczacki (SJ)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.

Manuel Stucki (M)

Department of Gynecology, University of Zurich, Schlieren, Switzerland.

Quynh-Thu Le (QT)

Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Simon J Leedham (SJ)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Amato J Giaccia (AJ)

Department of Oncology, University of Oxford, Oxford, United Kingdom.
Department of Radiation Oncology, Stanford University, Stanford, California, USA.

Monica M Olcina (MM)

Department of Oncology, University of Oxford, Oxford, United Kingdom.
Department of Radiation Oncology, Stanford University, Stanford, California, USA.
Department of Gynecology, University of Zurich, Schlieren, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH